SCHEMBL583189

SCHEMBL583189

CC(C)(O)CC(Cl)(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38006 0.76
SCHEMBL30227151 0.72 ALDH1A1 (0.50)
SCHEMBL8228599 0.71
SCHEMBL4318488 0.69 ALDH1A1 (0.47)
SCHEMBL9151652 0.69
SCHEMBL19381 0.69
SCHEMBL16671676 0.69
SCHEMBL5087641 0.69
SCHEMBL102085 0.69
SCHEMBL5720348 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024011218-A1 POLYMERIC NANOPARTICLES FOR LONG ACTING DELIVERY OF A PEPTIDE AND METHODS OF MAKING AND USING THEREOF BROWN UNIVERSITY (US) 2024-01-11 WO disclosed
CN-113057942-A Nano-particles containing hydrophobic drug, composition and application thereof 正大天晴药业集团股份有限公司 2021-07-02 CN disclosed
EP-2288340-B1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE LLC (US) 2020-06-24 EP disclosed
EP-2416650-B1 NANOPARTICLE FORMULATIONS AND USES THEROF ABRAXIS BIOSCIENCE LLC (US) 2020-02-26 EP disclosed
CN-105727303-B A kind of high albumin composition for carrying Cabazitaxel drug and its preparation and preparation method 四川科伦药物研究院有限公司 2019-06-28 CN disclosed
US-20180289620-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2018-10-11 US disclosed
US-20170172975-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2017-06-22 US disclosed
CN-105727303-A Albumin composition highly-carrying cabazitaxel medicine, preparation and preparation method thereof 四川科伦药物研究院有限公司 2016-07-06 CN disclosed
US-20140302157-A1 NANOPARTICLE FORMULATIONS AND USES THEROF ABRAXIS BIOSCIENCE, LLC (US) 2014-10-09 US disclosed
US-20140080901-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC (US) 2014-03-20 US disclosed
EP-2288340-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF Abraxis BioScience, LLC (US) 2011-03-02 EP disclosed
WO-2010118365-A1 NANOPARTICLE FORMULATIONS AND USES THEROF ABRAXIS BIOSCIENCE, LLC (US) 2010-10-14 WO disclosed
US-20090263483-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCE, LLC 2009-10-22 US disclosed
WO-2009126401-A1 COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF ABRAXIS BIOSCIENCE, LLC (US) 2009-10-15 WO disclosed
WO-2009126938-A1 NANOPARTICLE FORMULATIONS AND USES THEREOF ABRAXIS BIOSCIENCES, LLC (US) 2009-10-15 WO disclosed
WO-2009126175-A1 COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF ABRAXIS BIOSCIENCE, LLC (US) 2009-10-15 WO disclosed
US-5086045-A Antitumor antibiotic BRISTOL-MYERS SQUIBB COMPANY (US) 1992-02-04 US disclosed
US-5028536-A Biosynthesis BRISTOL-MYERS SQUIBB COMPANY (US) 1991-07-02 US disclosed
EP-0387860-A2 Antitumor antibiotic BMY-41339 Bristol-Myers Squibb Company (US) 1990-09-19 EP disclosed
US-4863988-A CHLORINATED GRAFT-MODIFIED POLYPROPYLENE MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1989-09-05 US disclosed